Clinical trial · Interventional
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
DECOMPRESS (DECompressing Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study stopped due to lack of accrual
Summary
Brief summary (as posted)
This research study will compare two procedures commonly used to treat urinary obstruction due to cancer. Sometimes cancer blocks one or both ureters (narrow tubes in the body that carry urine from the kidneys to the bladder). When these ureters become blocked, the body can no longer properly drain urine. This blocking of the ureters is called urinary obstruction, which can lead to kidney problems, infection, and pain. Treatment options for urinary obstruction include ureteral stent placement and percutaneous nephrostomy tube placement. Both treatment options require a doctor to place soft tubes (like a catheter) inside the body to help the ureters properly drain urine. These two treatment options have different success rates, risks, and effects on quality of life. By doing this study, researchers hope to learn which treatment option is best for individuals who develop urinary obstruction because of cancer. Participation in this research will last about 3 months.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Malignancy | Malignant Neoplasm | ALIAS | 0.90 |
| Ureter Injury | — | UNRESOLVED | — |
| Ureter Obstruction | — | UNRESOLVED | — |
| Urinary Dysfunction | — | UNRESOLVED | — |
| Urinary Obstruction | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous Nephrostomy Tube Placement | Device | — | UNRESOLVED |
| Ureteral Stent | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group A (Ureteral Stenting)
- description
- Group A: Participants in this group will receive a standard of care ureteral stenting performed by a urologist.
- interventionNames
- Device: Ureteral Stent
- type
- EXPERIMENTAL
- label
- Group B (Percutaneous Nephrostomy)
- description
- Participants in this group will receive a standard of care percutaneous nephrostomy tube placement performed by an interventional radiologist.
- interventionNames
- Device: Percutaneous Nephrostomy Tube Placement
Primary outcomes (1)
- measure
- Trial Feasibility (as assessed by number of enrolled and recruited patients)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Patients must have unilateral or bilateral hydronephrosis secondary to extrinsic compression by malignancy on cross sectional imaging. * Age ≥18 years. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria * Anticoagulation that cannot be safely reversed in the peri-procedural time period. * History of severe allergy to contrast media. * Prior stent or nephrostomy in previous 6 months. * Urethral or ureteric stricture disease. * Lower urinary tract structural abnormalities or urinary diversion precluding retrograde ureteral stent placement. * On blood pressure support or clinically unstable. * Pregnant women are excluded from this study because the radiation from either procedure is known to have the potential for teratogenic or abortifacient effects. * Previous renal transplant. * Dialysis
References
Publications (0)
Data not yet available